Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of VELCADE in combination with Rituximab in relapsed or progressive follicular non-Hodgkin lymphoma
2006-002521-23Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and rituximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoint: Clinical and molecular overall response rate. Started Jul 2007; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2006-002521-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002521-23.